Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study

References

• Isaacson PG, Piris MA, Berger F, et al. Splenic B-cell marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp 185–187.
   Google Scholar
• Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood 2003;101:2464–2472.
   PubMed Web of Science ®Google Scholar
• Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev 2005;19:39–51.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003;4:95–103.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer 2004;101:2050–2057.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 2002;3:41–47.
   PubMedGoogle Scholar
• Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006;107: 4643–4649.
   PubMed Web of Science ®Google Scholar
• Chacón JI, Mollejo M, Muñoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100:1648 –1654.
   PubMed Web of Science ®Google Scholar
• Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 2001;25:1268 –1276.
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Appiah-Cubi S, Kulkarni S, et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol 2008;143:71–74.
   PubMed Web of Science ®Google Scholar
• Parry-Jones N, Matutes E, Gruszca-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003;120:759–764.
   PubMed Web of Science ®Google Scholar
• Lenglet J, Traullé C, Mounier N, et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma 2014;55:1854–1860.
   PubMed Web of Science ®Google Scholar
• Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma: proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008;22:487–495.
   PubMed Web of Science ®Google Scholar
• Matutes E. Splenic marginal zone lymphoma: disease features and management. Expert Rev Hematol 2013;6:735–745.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Tripodo C. How I diagnose and treat splenic lymphomas. Blood 2011;117:2585–2595.
   PubMed Web of Science ®Google Scholar
• Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol 2010;147:143–147.
   Web of Science ®Google Scholar
• Else M, Marín-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 2012;159:322–328.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist 2013;18:190–197.
   PubMed Web of Science ®Google Scholar
• Cervetti G, Galimberti S, Pelosini M, et al. Significant efficacy of 2-chlorodeoxyadenosine {+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Ann Oncol 2013;24:2434–2438.
   PubMed Web of Science ®Google Scholar
• Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003;14: 239–246.
   PubMed Web of Science ®Google Scholar
• Mross K, Niemann B, Massing U, et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol 2004;54:514–524.
   PubMed Web of Science ®Google Scholar
• Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol 2010;21:1492–1499.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials 1989;10:1–10.
   PubMedGoogle Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford: Blackwell Science; 1987.
   Google Scholar
• Montalbán C, Abraira V, Arcaini L, et al. ;Splenic Marginal Zone Lymphoma Study Group. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol 2012;159: 164–171.
   PubMed Web of Science ®Google Scholar
• Dell’Olio M, Scalzulli RP, Sanpaolo G, et al. Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2011;52:1222–1229.
   PubMed Web of Science ®Google Scholar
• Visani G, Ferrara F, Alesiani F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma 2008;49:1081–1086.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Callea V, et al. Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma. Eur J Haematol 2006;76:134–140.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol 2014;93:449–458.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006;107:125–135.
   PubMed Web of Science ®Google Scholar
• Ponzoni M, Kanellis G, Pouliou E, et al. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? Am J Surg Pathol 2012;36: 1609–1618.
   PubMed Web of Science ®Google Scholar